The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab

[1]  S. Tuță,et al.  Double seropositive neuromyelitis optica associated with COVID-19: A case report , 2022, Frontiers in Neurology.

[2]  B. Weinshenker,et al.  Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials , 2021, Nature Reviews Neurology.

[3]  H. Hartung,et al.  Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[4]  F. Paul,et al.  Neuromyelitis optica , 2020, Nature Reviews Disease Primers.

[5]  N. Reyes,et al.  Binding mechanisms of therapeutic antibodies to human CD20 , 2020, Science.

[6]  Jeffrey A. Cohen,et al.  Ofatumumab versus Teriflunomide in Multiple Sclerosis. , 2020, The New England journal of medicine.

[7]  J. Avasarala,et al.  Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis. , 2020, Multiple sclerosis and related disorders.

[8]  T. Misu,et al.  Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial , 2020, The Lancet Neurology.

[9]  O. Boespflug-Tanguy,et al.  Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[10]  Jae-Won Hyun,et al.  Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder , 2019, Neurochemistry International.

[11]  J. Tolson,et al.  Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study , 2019, Neurology.

[12]  M. Reindl,et al.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease , 2018, Nature Reviews Neurology.

[13]  D. Isenberg,et al.  Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus , 2018, Annals of the rheumatic diseases.

[14]  V. Damato,et al.  Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. , 2016, JAMA neurology.

[15]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[16]  John J. Chen,et al.  Optic Neuritis In the Era of Biomarkers. , 2019, Survey of ophthalmology.